Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (002864) — Net Asset Quality Index
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (002864) has a Net Asset Quality Index of 70.3% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.43 Billion minus total liabilities of CN¥721.64 Million yields net assets of CN¥1.71 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check financial resilience of Shaanxi Panlong Pharmaceutical Group Lim to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A Net Asset Quality Index Over Time (2013–2025)
This chart shows how Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's Net Asset Quality Index has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the index stands at 70.3%, representing net assets of CN¥1.71 Billion against total assets of CN¥2.43 Billion CNY. See Shaanxi Panlong Pharmaceutical Group Lim (002864) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (2013–2025)
The table below presents the year-by-year Net Asset Quality Index for Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A from 2013 to 2025, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Shaanxi Panlong Pharmaceutical Group Lim (002864) total market value.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 72.7% | CN¥1.69 Billion | CN¥2.32 Billion | CN¥633.75 Million | ▲ +0.9 pp |
| 2024 | 71.8% | CN¥1.64 Billion | CN¥2.28 Billion | CN¥642.84 Million | ▼ -1.2 pp |
| 2023 | 73.0% | CN¥1.55 Billion | CN¥2.13 Billion | CN¥573.76 Million | ▲ +23.9 pp |
| 2022 | 49.1% | CN¥947.60 Million | CN¥1.93 Billion | CN¥983.18 Million | ▼ -11.6 pp |
| 2021 | 60.7% | CN¥807.21 Million | CN¥1.33 Billion | CN¥522.97 Million | ▼ -2.6 pp |
| 2020 | 63.3% | CN¥735.66 Million | CN¥1.16 Billion | CN¥426.89 Million | ▼ -9.4 pp |
| 2019 | 72.6% | CN¥674.71 Million | CN¥928.88 Million | CN¥254.17 Million | ▼ -2.1 pp |
| 2018 | 74.8% | CN¥611.60 Million | CN¥817.84 Million | CN¥206.24 Million | ▲ +1.0 pp |
| 2017 | 73.8% | CN¥555.58 Million | CN¥752.93 Million | CN¥197.34 Million | ▲ +8.8 pp |
| 2016 | 65.0% | CN¥327.82 Million | CN¥504.50 Million | CN¥176.68 Million | ▼ -1.7 pp |
| 2015 | 66.7% | CN¥288.89 Million | CN¥433.33 Million | CN¥144.44 Million | ▲ +5.3 pp |
| 2014 | 61.4% | CN¥246.19 Million | CN¥401.26 Million | CN¥155.06 Million | ▼ -0.2 pp |
| 2013 | 61.6% | CN¥210.84 Million | CN¥342.39 Million | CN¥131.55 Million | — |